XORTX Therapeutics (XRTX) Stock: Buy, Sell, or Hold?
XRTX - XORTX Therapeutics Inc. Common Stock
$1.72
0.31 (21.99%)
▲
5d:
+1.18%
30d:
-26.18%
90d:
-14.43%
HOLD
LOW Confidence
Analysis Updated: Oct 12, 2026 12:00 AM ET
Earnings: Nov 13, 2026
30d
Get Alerted When XRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XRTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: XRTX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.62
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.63
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XRTX is currently trading at $1.72, which is considered slightly low relative to its 30-day fair value range of $1.63 to $2.09. The stock's valuation (Forward PE: 1.6) is in line with its historical norms (1.7). Remarkably, the market is currently pricing in an annual earnings decline of 3.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XRTX is in a downtrend. Immediate support is located at $1.36, while resistance sits at $2.08. The stock is showing strong short-term momentum, up 22.0% recently.
Market Sentiment: XRTX scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.04 (+716.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XRTX is in a downtrend. Immediate support is located at $1.36, while resistance sits at $2.08. The stock is showing strong short-term momentum, up 22.0% recently.
Market Sentiment: XRTX scores 79/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $14.04 (+716.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.63 -
$2.09
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (79/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+22.0%)
- BULLISH: Trading 716.0% below Wall St target ($14.04)
- CAUTION: Bottoming setup, but lagging the sector by 26% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$1.63 -
$2.09
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.36
Resistance Level
$2.08
Current Trend
Downtrend
Technical data as of
Oct 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.56
Wall Street Target
$14.04
(+716.0%)
Earnings Growth (YoY)
-97.2%
Valuation Discount vs History
-3.5% cheaper
PE vs Historical
1.6 vs 1.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.5%
(market-implied from PE analysis)
1-Year Target
$1.66
(-4%)
2-Year Target
$1.60
(-7%)
3-Year Target
$1.55
(-10%)
3-Yr Target (if PE normalizes)
(PE: 2→2)
$1.68
(-2%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.6 to 1.7
Stabilization Target:
$1.87
(+8.8%)
PE Expansion Potential:
+8.8%
Share & Embed Analysis
Last updated: October 13, 2026 7:13 AM ET
Data refreshes hourly during market hours. Next update: 8:13 AM
Data refreshes hourly during market hours. Next update: 8:13 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
BUY
27 analysts |
$859 | 57 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 71 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 43 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$32 | 64 BUY |
|
PHVS
Pharvaris BV |
STRONG BUY
14 analysts |
$57 | 72 BUY |
